- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07297745
Prövning av Aldosteron-hybridsteRoid för att vägleda kurativ behandling av primär hyperaldosteronism
Studie av Aldosteron-hybridsteroid för att vägleda botande behandling av primär aldosteronism
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Primary Aldosteronism is a common but under-diagnosed condition, despite being a curable cause of secondary hypertension with significant long-term health consequences if left untreated. Once the diagnosis of primary aldosteronism is confirmed, subtype tests are required to demonstrate unilateral primary aldosteronism before curative surgery. Most patients need to undergo adrenal vein sampling, an invasive procedure performed under radiological guidance. However, this procedure is technically-challenging, with failure to cannulate both adrenal veins frequently leading to inconclusive results. Many patients worldwide may be offered surgery based on computed tomography imaging alone because of a lack of adrenal vein sampling expertise or a failed adrenal vein sampling result.
High hybrid hormones indicate a functional KCNJ5-mutant aldosterone-producing adenoma and, when coupled with computed tomography imaging, may provide a non-invasive alternative to adrenal vein sampling for identifying unilateral primary aldosteronism.
Ultimately, this trial aims to reduce the number of patients that will require an invasive adrenal vein sampling in future clinical diagnostics. This will improve access, and allow more patients to receive timely and curative treatment.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Troy H Puar, FRCP, PhD
- Telefonnummer: 67888833
- E-post: troy_puar@cgh.com.sg
Studieorter
-
-
-
Singapore, Singapore
- Rekrytering
- National University Hospital
-
Kontakt:
- Ada Teo
- Telefonnummer: +65 6908 2222
- E-post: ada_ed_teo@nuhs.edu.sg
-
Huvudutredare:
- Ada Teo
-
Singapore, Singapore
- Rekrytering
- Singapore General Hospital
-
Kontakt:
- Swee Du Soon
- Telefonnummer: +65 6222 3322
- E-post: swee.du.soon@singhealth.com.sg
-
Huvudutredare:
- Swee Du Soon
-
Singapore, Singapore
- Har inte rekryterat ännu
- Khoo Teck Puat Hospital
-
Kontakt:
- Niyati Jauhar
- Telefonnummer: +65 6555 8000
- E-post: jauhar.niyati@nhghealth.com.sg
-
Huvudutredare:
- Niyati Jauhar
-
Singapore, Singapore
- Har inte rekryterat ännu
- Tan Tock Seng Hospital
-
Kontakt:
- Lai Tian Rui Ray
- Telefonnummer: +65 6357 3078
- E-post: ray.tr.lai@nhghealth.com.sg
-
Huvudutredare:
- Lai Tian Rui Ray
-
Singapore, Singapore
- Rekrytering
- Sengkang General Hospital
-
Kontakt:
- Matthew Chuah
- Telefonnummer: +65 6930 5000
- E-post: matthew.chuah@singhealth.com.sg
-
Huvudutredare:
- Matthew Chuah Bingfeng
-
-
Singapore
-
Singapore, Singapore, Singapore, 529889
- Rekrytering
- Changi General Hospital
-
Kontakt:
- Troy H Puar, FRCP, PhD
- Telefonnummer: +65 68503967
- E-post: troy_puar@cgh.com.sg
-
Huvudutredare:
- Troy H Puar, FRCP, PhD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.
- Willing to undergo subtype testing with adrenal vein sampling and/or molecular imaging (Positron Emission Tomography/Computed Tomography, PET/CT).
- Keen for surgical treatment if shown to have unilateral primary aldosteronism.
Exclusion Criteria:
- Inability to provide written informed consent.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Diagnostisk
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Hybrid hormones
Previous studies have shown that hybrid hormones are elevated in patients with unilateral primary aldosteronism who have large, visible adenomas in their adrenal glands. These tumors harbour a somatic KCNJ5 mutation and are also most likely to be cured of hypertension after surgery. Hence, the investigators hypothesize that high hybrid hormones levels, in the presence of an adenoma on a computed tomography imaging would identify study participants who can proceed to surgery. |
Participants will have a baseline blood sample taken so the investigators can measure the adrenal steroid biomarkers 18-oxocortisol, 18-hydroxylcortisol and other steroids. The collected plasma or serum will then be analyzed in the laboratory using validated methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), to determine the levels of these biomarkers. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants with complete biochemical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Tidsram: 6 months
|
Proportion of participants with correction of hypokalaemia and normalisation of aldosterone-renin-ratio following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Proportion of participants with KCNJ5-mutant aldosterone producing adenoma/nodule
Tidsram: 6 months
|
Proportion of participants with histopathology and genetic confirmation of KCNJ5-mutant aldosterone producing adenoma/nodule in resected adrenals. |
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Proportion of participants with complete clinical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Tidsram: 6 months
|
Proportion of participants with reduction in blood pressure and reduction anti-hypertensive medication following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Cost-effectiveness of using hybrid hormones coupled with computed tomography imaging versus other subtyping tests including adrenal vein sampling and/or molecular imaging in diagnosing participants with unilateral primary aldosteronism
Tidsram: 6 months
|
Cost-effectiveness of the diagnostic course will be calculated by using calculated costs per quality-adjusted life years (QALYs) |
6 months
|
|
Diagnostic criteria using hybrid hormones/ steroid profiling coupled with computed tomography imaging
Tidsram: 6 months
|
The criteria of hybrid hormones/ steroid profiling coupled with computed tomography imaging which offer the best sensitivity and specificity for lateralization of aldosterone-producing adenoma. |
6 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Troy Puar, FRCP, PhD, Changi General Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TARGET-PA
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .